We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Bipolar disorder, formerly known as manic-depressive disorder, is a mental health disorder that can cause extreme mood swings, including high mood (mania or mild hypomania) and low mood (depression). Ace Therapeutics provides preclinical research and development services for bipolar disorder, helping clients accelerate the translation of novel therapies from the lab to the clinic. Our services include drug screening, design optimization, ex vivo and in vivo efficacy evaluation, safety testing, pharmacokinetic studies, and biomarker identification and validation. Our services are designed to provide pharmaceutical companies and research institutions with comprehensive, customized solutions to help clients achieve key breakthroughs in the early stages of bipolar disorder drug discovery and development, and to identify a solid foundation for more effective and safer therapeutic options.
The pathophysiology of BD involves interactions between multiple genetic, neurochemical, and environmental factors. Ace Therapeutics combines animal models, cellular models, and our advanced technologies to help clients delve deeper into the genetic components, signaling pathways, biochemical changes, and neuroimaging findings associated with BD. Our services are designed to assist clients in gaining a deeper understanding of the disease's underlying pathophysiology and neurobiological mechanisms, thereby advancing the development of effective drugs.
Ace Therapeutics provides preclinical development services for anti-bipolar disorder drugs. Our services can effectively improve the efficiency and success of drug studies and ultimately accelerate the process of bringing new drugs to market. Our services include the following areas
Ace Therapeutics is dedicated to assisting clients in the discovery and validation of BD-related neuroimaging biomarkers and peripheral blood biomarkers. Our objective is to facilitate the early identification and accurate diagnosis of the disease. Our comprehensive BD biomarker research services provide a solid scientific foundation for the development of in vitro diagnostic (IVD) and prompt oncology testing (POCT) products. They also help our clients advance in the field of precision medicine by promoting the innovation of bipolar disorder diagnostic technology.
Ace Therapeutics has a professional and experienced R&D team that can provide the right solutions and solutions to ensure quality and efficiency in all aspects of the drug development process. We also have the relevant certifications and qualifications to ensure the legitimacy and compliance of the R&D process. If you are interested in our services, please contact us to learn how we can support you in your project.
Enter your E-mail and receive the latest news from us